SV2016005312A - Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cã�ncer - Google Patents
Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cã�ncerInfo
- Publication number
- SV2016005312A SV2016005312A SV2016005312A SV2016005312A SV2016005312A SV 2016005312 A SV2016005312 A SV 2016005312A SV 2016005312 A SV2016005312 A SV 2016005312A SV 2016005312 A SV2016005312 A SV 2016005312A SV 2016005312 A SV2016005312 A SV 2016005312A
- Authority
- SV
- El Salvador
- Prior art keywords
- compounds
- salts
- ona
- quinolin
- descriptive memory
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 8
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000000543 intermediate Substances 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- -1 COMPOUND COMPOUNDS Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
LA MEMORIA DESCRIPTIVA SE REFIERE GENERALMENTE A LOS COMPUESTOS DE FÓRMULA (I): (VER FORMULA); Y LAS SALES FARMACÉUTICAMENTE ACEPTABLES DE ESTOS, DONDE Q, R1, R2, R3, R4 Y R5 TIENEN CUALQUIERA DE LOS SIGNIFICADOS DEFINIDOS EN LA PRESENTE. LA MEMORIA DESCRIPTIVA TAMBIÉN SE REFIERE AL USO DE TALES COMPUESTOS Y SALES DE ESTOS PARA TRATAR O PREVENIR ENFERMEDADES MEDIADAS POR LA CINASA ATM, INCLUYENDO EL C�NCER. LA MEMORIA DESCRIPTIVA ADEM�S SE REFIERE A LAS FORMAS CRISTALINAS DE LOS COMPUESTOS DE COMPUESTOS IMIDAZO[4,5-C]QUINOLIN-2-ONA Y LAS SALES FARMACÉUTICAMENTE ACEPTABLES DE ESTOS; LAS COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN TALES COMPUESTOS Y SALES; LOS KITS QUE COMPRENDEN TALES COMPUESTOS Y SALES; LOS MÉTODOS DE FABRICACIÓN DE TALES COMPUESTOS Y SALES; LOS INTERMEDIOS ÚTILES EN LA FABRICACIÓN DE TALES COMPUESTOS Y SALES; Y LOS MÉTODOS PARA TRATAR ENFERMEDADES MEDIADAS POR LA CINASA ATM, INCLUYENDO EL C�NCER, UTILIZANDO TALES COMPUESTOS Y SALES
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461990232P | 2014-05-08 | 2014-05-08 | |
| PCT/GB2015/051312 WO2015170081A1 (en) | 2014-05-08 | 2015-05-05 | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SV2016005312A true SV2016005312A (es) | 2017-03-16 |
Family
ID=53264681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SV2016005312A SV2016005312A (es) | 2014-05-08 | 2016-11-08 | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cã�ncer |
Country Status (39)
| Country | Link |
|---|---|
| US (4) | US9428503B2 (es) |
| EP (1) | EP3140303B1 (es) |
| JP (1) | JP6505131B2 (es) |
| KR (1) | KR102013021B1 (es) |
| CN (1) | CN106255692B (es) |
| AP (1) | AP2016009532A0 (es) |
| AR (1) | AR100340A1 (es) |
| AU (1) | AU2015257456B2 (es) |
| CA (1) | CA2946459C (es) |
| CL (1) | CL2016002735A1 (es) |
| CR (1) | CR20160523A (es) |
| CY (1) | CY1120248T1 (es) |
| DK (1) | DK3140303T3 (es) |
| DO (1) | DOP2016000281A (es) |
| EA (1) | EA031674B1 (es) |
| ES (1) | ES2670416T3 (es) |
| HR (1) | HRP20180697T1 (es) |
| HU (1) | HUE037558T2 (es) |
| IL (1) | IL248397B (es) |
| LT (1) | LT3140303T (es) |
| MA (1) | MA39960A (es) |
| MX (1) | MX374401B (es) |
| NI (1) | NI201600166A (es) |
| NO (1) | NO2714752T3 (es) |
| NZ (1) | NZ726042A (es) |
| PE (1) | PE20170403A1 (es) |
| PH (1) | PH12016502168B1 (es) |
| PL (1) | PL3140303T3 (es) |
| PT (1) | PT3140303T (es) |
| RS (1) | RS57223B1 (es) |
| SG (1) | SG11201609164VA (es) |
| SI (1) | SI3140303T1 (es) |
| SM (1) | SMT201800259T1 (es) |
| SV (1) | SV2016005312A (es) |
| TN (1) | TN2016000458A1 (es) |
| TR (1) | TR201807101T4 (es) |
| TW (1) | TWI662034B (es) |
| UY (1) | UY36112A (es) |
| WO (1) | WO2015170081A1 (es) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111689963A (zh) * | 2015-04-02 | 2020-09-22 | 默克专利股份公司 | 咪唑酮基喹啉和其作为atm激酶抑制剂的用途 |
| GB201516504D0 (en) * | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
| GB201519406D0 (en) * | 2015-11-03 | 2015-12-16 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
| GB201519568D0 (en) * | 2015-11-05 | 2015-12-23 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
| TWI827530B (zh) * | 2016-02-15 | 2024-01-01 | 瑞典商阿斯特捷利康公司 | 包括對西地尼布進行固定的間歇給藥之方法 |
| JP2019512512A (ja) * | 2016-03-21 | 2019-05-16 | アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ | シンノリン−４−アミン化合物およびその癌治療への使用 |
| US20190119270A1 (en) * | 2016-04-07 | 2019-04-25 | Astrazeneca Ab | N-Oxide Compound and Its Use in Treating Cancer |
| GB201608227D0 (en) * | 2016-05-11 | 2016-06-22 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
| HRP20210548T1 (hr) | 2016-12-20 | 2021-05-14 | Astrazeneca Ab | Spojevi amino-triazolopiridina i njihova uporaba u liječenju raka |
| US10874670B2 (en) | 2017-01-09 | 2020-12-29 | Impact Therapeutics, Inc. | Substituted fused heteroaromatic compounds as kinase inhibitors and the use thereof |
| CN106692147A (zh) * | 2017-02-07 | 2017-05-24 | 李明英 | 一种治疗男性不育的药物组合物 |
| CN106798741A (zh) * | 2017-02-07 | 2017-06-06 | 宫英 | 一种治疗抑郁症的药物组合物 |
| CN106822123A (zh) * | 2017-02-09 | 2017-06-13 | 王艳苓 | 一种治疗心脑血管疾病的药物组合物 |
| WO2018153365A1 (zh) | 2017-02-27 | 2018-08-30 | 上海瑛派药业有限公司 | 取代的稠合杂芳三环化合物作为激酶抑制剂及其应用 |
| JOP20190209A1 (ar) * | 2017-03-16 | 2019-09-12 | Astrazeneca Ab | مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان |
| WO2019057757A1 (en) | 2017-09-20 | 2019-03-28 | Astrazeneca Ab | 1,3-DIHYDROIMIDAZO [4,5-C] CINNOLIN-2-ONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER |
| WO2019201283A1 (en) * | 2018-04-20 | 2019-10-24 | Xrad Therapeutics, Inc. | Dual atm and dna-pk inhibitors for use in anti-tumor therapy |
| CN110386932A (zh) * | 2018-04-20 | 2019-10-29 | 艾科思莱德制药公司 | 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂 |
| WO2020052688A1 (en) * | 2018-09-14 | 2020-03-19 | Suzhou Zanrong Pharma Limited | 1-ISOPROPYL-3-METHYL-8- (PYRIDIN-3-YL) -1, 3-DIHYDRO-2H-IMIDAZO [4, 5-c] CINNOLIN-2-ONE AS SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE AND USES THEREOF |
| JP2022505041A (ja) * | 2018-10-15 | 2022-01-14 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｄｎａアルキル化剤及びａｔｒ阻害剤を使用する併用療法 |
| AU2020231045B2 (en) * | 2019-03-05 | 2023-03-16 | Astrazeneca Ab | Fused tricyclic compounds useful as anticancer agents |
| TW202102497A (zh) * | 2019-03-29 | 2021-01-16 | 瑞典商阿斯特捷利康公司 | 化合物及它們在治療癌症中之用途 |
| CN111909147B (zh) * | 2019-05-10 | 2021-07-20 | 山东轩竹医药科技有限公司 | Dna-pk抑制剂 |
| WO2021004482A1 (zh) * | 2019-07-10 | 2021-01-14 | 上海瑛派药业有限公司 | 取代的吡唑并喹唑啉酮化合物及其应用 |
| CN114787162B (zh) * | 2019-09-12 | 2024-09-03 | 上海瑛派药业有限公司 | 取代的咪唑并喹喔啉化合物及其应用 |
| WO2021139814A1 (zh) * | 2020-01-09 | 2021-07-15 | 南京明德新药研发有限公司 | 喹啉并咪唑类化合物及其应用 |
| CN114980900A (zh) * | 2020-01-13 | 2022-08-30 | 上海华禹生物科技有限公司 | N2-喹啉或异喹啉取代的嘌呤衍生物在癌症治疗中的用途 |
| EP4171651A1 (en) * | 2020-06-24 | 2023-05-03 | AstraZeneca UK Limited | Combination of antibody-drug conjugate and atm inhibitor |
| EP3992191A1 (en) | 2020-11-03 | 2022-05-04 | Deutsches Krebsforschungszentrum | Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors |
| AU2021433713A1 (en) * | 2021-03-17 | 2023-09-28 | Suzhou Zanrong Pharma Limited | Selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0211649D0 (en) * | 2002-05-21 | 2002-07-03 | Novartis Ag | Organic compounds |
| KR20060117329A (ko) | 2003-11-21 | 2006-11-16 | 노파르티스 아게 | 단백질 키나제 저해제로서의 1ｈ-이미다조퀴놀린 유도체 |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| PE20090717A1 (es) * | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| KR20110029161A (ko) | 2008-07-01 | 2011-03-22 | 제넨테크, 인크. | Ｍｅｋ 키나제 억제제로서의 비시클릭 헤테로사이클 |
| ES2614130T3 (es) | 2008-09-30 | 2017-05-29 | Pfizer Inc. | Compuestos de imidazo[1,5]naftiridina, su uso farmacéutico y composiciones |
| TW201041888A (en) * | 2009-05-06 | 2010-12-01 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| WO2010139747A1 (en) * | 2009-06-04 | 2010-12-09 | Novartis Ag | 1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES |
| CA2763821A1 (en) | 2009-06-04 | 2010-12-09 | Novartis Ag | 1h-imidazo[4,5-c]quinolinone derivatives |
| KR20140034948A (ko) * | 2009-09-28 | 2014-03-20 | 에프. 호프만-라 로슈 아게 | 벤즈옥세핀 ｐｉ3ｋ 억제제 화합물 및 사용 방법 |
| GB0919423D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| CN102199152A (zh) | 2010-03-25 | 2011-09-28 | 高大新 | 杂环咪唑类磷脂激酶抑制剂 |
| CN102372711B (zh) | 2010-08-18 | 2014-09-17 | 山东轩竹医药科技有限公司 | 咪唑并喹啉类PI3K和mTOR双重抑制剂 |
| WO2012026233A1 (ja) | 2010-08-26 | 2012-03-01 | 日立建機株式会社 | 建設機械 |
| DE102010035744A1 (de) | 2010-08-28 | 2012-03-01 | Merck Patent Gmbh | Imidazolonylchinoline |
| CN102399218A (zh) | 2010-09-16 | 2012-04-04 | 和记黄埔医药（上海）有限公司 | 一类并合三杂环及其作为pi3k抑制剂的用途 |
| CA2819955A1 (en) | 2010-12-06 | 2012-06-14 | Piramal Enterprises Limited | Substituted imidazoquinoline derivatives |
| AU2012240246A1 (en) | 2011-04-04 | 2013-05-09 | Netherlands Cancer Institute | Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors |
| JP6042060B2 (ja) * | 2011-09-26 | 2016-12-14 | サノフイ | ピラゾロキノリノン誘導体、その調製および治療上の使用 |
-
2012
- 2012-05-25 NO NO12793015A patent/NO2714752T3/no unknown
-
2015
- 2015-05-05 SG SG11201609164VA patent/SG11201609164VA/en unknown
- 2015-05-05 AU AU2015257456A patent/AU2015257456B2/en active Active
- 2015-05-05 AP AP2016009532A patent/AP2016009532A0/en unknown
- 2015-05-05 PT PT157243510T patent/PT3140303T/pt unknown
- 2015-05-05 PE PE2016002124A patent/PE20170403A1/es unknown
- 2015-05-05 NZ NZ726042A patent/NZ726042A/en not_active IP Right Cessation
- 2015-05-05 CA CA2946459A patent/CA2946459C/en active Active
- 2015-05-05 HU HUE15724351A patent/HUE037558T2/hu unknown
- 2015-05-05 RS RS20180593A patent/RS57223B1/sr unknown
- 2015-05-05 SI SI201530247T patent/SI3140303T1/en unknown
- 2015-05-05 US US14/704,031 patent/US9428503B2/en active Active
- 2015-05-05 DK DK15724351.0T patent/DK3140303T3/en active
- 2015-05-05 EP EP15724351.0A patent/EP3140303B1/en active Active
- 2015-05-05 LT LTEP15724351.0T patent/LT3140303T/lt unknown
- 2015-05-05 CN CN201580022454.1A patent/CN106255692B/zh active Active
- 2015-05-05 TR TR2018/07101T patent/TR201807101T4/tr unknown
- 2015-05-05 SM SM20180259T patent/SMT201800259T1/it unknown
- 2015-05-05 MA MA039960A patent/MA39960A/fr unknown
- 2015-05-05 JP JP2016567002A patent/JP6505131B2/ja active Active
- 2015-05-05 PL PL15724351T patent/PL3140303T3/pl unknown
- 2015-05-05 EA EA201692095A patent/EA031674B1/ru not_active IP Right Cessation
- 2015-05-05 HR HRP20180697TT patent/HRP20180697T1/hr unknown
- 2015-05-05 CR CR20160523A patent/CR20160523A/es unknown
- 2015-05-05 ES ES15724351.0T patent/ES2670416T3/es active Active
- 2015-05-05 TN TN2016000458A patent/TN2016000458A1/en unknown
- 2015-05-05 WO PCT/GB2015/051312 patent/WO2015170081A1/en not_active Application Discontinuation
- 2015-05-05 MX MX2016014639A patent/MX374401B/es active IP Right Grant
- 2015-05-05 KR KR1020167034005A patent/KR102013021B1/ko active Active
- 2015-05-06 UY UY0001036112A patent/UY36112A/es not_active Application Discontinuation
- 2015-05-07 AR ARP150101395A patent/AR100340A1/es not_active Application Discontinuation
- 2015-05-08 TW TW104114814A patent/TWI662034B/zh active
-
2016
- 2016-07-22 US US15/217,079 patent/US9822111B2/en active Active
- 2016-10-19 IL IL248397A patent/IL248397B/en active IP Right Grant
- 2016-10-19 DO DO2016000281A patent/DOP2016000281A/es unknown
- 2016-10-27 CL CL2016002735A patent/CL2016002735A1/es unknown
- 2016-11-02 PH PH12016502168A patent/PH12016502168B1/en unknown
- 2016-11-04 NI NI201600166A patent/NI201600166A/es unknown
- 2016-11-08 SV SV2016005312A patent/SV2016005312A/es unknown
-
2017
- 2017-10-17 US US15/785,974 patent/US10189834B2/en active Active
-
2018
- 2018-05-22 CY CY20181100532T patent/CY1120248T1/el unknown
- 2018-12-12 US US16/217,190 patent/US20190185468A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SV2016005312A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cã�ncer | |
| SV2018005663A (es) | Compuestos de imidazo [4,5-c] quinolin-2-ona y su uso en el tratamiento del cancer | |
| CL2019001714A1 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer. | |
| SV2016005330A (es) | Compuestos de 1,3,4-tiadiazol y uso de los mismos para el tratamiento del cã�ncer | |
| SV2018005680A (es) | Compuestos de imidazo [4,5-c] quinolin- 2-ona y su uso en el tratamiento del cancer | |
| DOP2016000140A (es) | Inhibidores de syk | |
| CU20180152A7 (es) | Pirimidin-2-ilamino-1h-pirazoles útiles como inhibidores de lrrk2 | |
| CU20160149A7 (es) | Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4 | |
| CR20150472A (es) | USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd | |
| DOP2018000065A (es) | Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cáncer | |
| AR102981A1 (es) | Inhibidores de la necrosis celular y métodos de preparación de los mismos | |
| UY36875A (es) | Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades | |
| SV2017005368A (es) | [1,2,4] triazolo [4,3-b] piridazinas para su uso en el tratamiento de enfermedades proliferativas | |
| GT201700126A (es) | Ácidos piridil-cicloalquil-carboxílicos sustituidos composiciones que los contienen y usos de los mismos | |
| DOP2018000197A (es) | Compuestos de cinnolin-4-amina y su uso en el tratamiento del cáncer | |
| CL2019002480A1 (es) | Derivados de pirazol como inhibidores de bromodominio. | |
| ECSP18056196A (es) | Derivados de indano | |
| AR102569A1 (es) | Síntesis de inhibidor de pi3k, formas cristalinas y sales del mismo y una composición farmacéutica que lo comprende | |
| ECSP13012372A (es) | Nuevos derivados 1,4-diazepanos, inhibidores de pde-5. | |
| AR096322A1 (es) | Derivados de pirimidin-4-il)oxi)-1h-indol-1-carboxamida y uso de los mismos |